NewAmsterdam Pharma N.V. (NAMS): Price to Sales

NewAmsterdam Pharma (NAMS) risks are tied to the outcome of cholesterol-lowering tests, which is confirmed by the price-to-sales ratio, where the indicator reaches 93.20. Such volatility is explained by the drive to capture the cardiometabolic market through the launch of an oral blockbuster. Meanwhile, a science-based image and physician trust create a solid foundation for the company's future growth.

NewAmsterdam Pharma Company N.V. - NAMS P/S Multiple (period 06/21/2023 - 11/15/2026)

Metric breakdowns and analytics for newamsterdampharma.com (NAMS)

- current price and projected stock value:

Price Chart NewAmsterdam Pharma Company|NAMS - Price Target Chart

- stock exchange capitalization data:

Market Value NewAmsterdam Pharma|NAMS - Total Company Value

- shareholders' equity book value data:

Net Assets per Single Share NewAmsterdam Pharma|NAMS - Book Capitalization|Market Capitalization to Book Value newamsterdampharma.com|NAMS - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

NAMS - Net Profit|Projected Future Earnings NewAmsterdam Pharma|NAMS - Price to Earnings Ratio|Projected Price to Earnings NewAmsterdam Pharma Corp|NAMS - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio NewAmsterdam Pharma Company N.V.|NAMS - Operating profit before deduction of amortization|Earnings per share for the last four quarters NewAmsterdam Pharma|NAMS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months newamsterdampharma.com|NAMS - Earnings per share growth in current year|Expected earnings per share trend next year NewAmsterdam Pharma

- issuer revenue and sales details:

NAMS - Revenue and Sales Volume|Company Revenue Forecast NewAmsterdam Pharma Company N.V.|NAMS - P/S Multiple|Forward P/S Multiple NewAmsterdam Pharma|NAMS - Sales Growth YoY (Last Twelve Months)

Fundamental company analysis:NewAmsterdam Pharma Company N.V. (NAMS)

For NewAmsterdam Pharma (NAMS), whose valuation is based on expectations from clinical trials of cardiovascular drugs, the company's P/S chart reflects the degree of market optimism regarding future revenues. This ratio, calculated as market capitalization divided by annual sales volume, allows for an assessment of the business's resilience to technological shocks and helps determine the risk of asset overvaluation relative to US industry averages.

Competing companies